MedCap Q3 Adjusted EBITA Rises 30%; Sales Increase 13%
MedCap reported Q3 net sales growth of 13%, including 5% organic growth. All business areas grew; Specialty Pharma benefited from the prior XGX acquisition and higher non-recurring unlicensed pharma sales.
MedCap said third-quarter net sales increased 13%, including 5% organic growth, while adjusted EBITA rose 30%. All business areas recorded growth. Assistive Tech and MedTech had strong margins, while Specialty Pharma benefited from the earlier XGX acquisition and higher non-recurring sales of unlicensed pharmaceuticals.